Unlocking patient access: Modernizing clinical trial regulatory frameworks and trial delivery
The rules that govern our clinical trial infrastructure were written decades ago and did not anticipate the advances we made to increase clinical trials access for patients, efficiency in delivery and lower burden for both investigators and patients.
Although the FDA’s recent Final Guidance on decentralized clinical trials was a significant step forward, the regulatory framework still prioritizes traditional study designs, tools, and infrastructure over more modern and accessible approaches such as community-based research. The result: many people are still hindered from participating in clinical trials.
In this discussion, you’ll learn:
- The remaining barriers that prevent community-based research and other clinical trial innovations from becoming standard practice.
- What can be done to remove those barriers to broaden patient access to clinical research.
Who should attend:
- Clinical trial regulators
- Study investigators & site staff
- Community-based physicians, providers
- Policymakers
- Biopharmaceutical industry
- Patient advocacy organizations
- Media
Join Eli Lilly and Company to examine the current barriers limiting access to clinical trial participation and how Eli Lilly and Company is working to modernize the trial landscape to increase patient participation and deliver innovative treatments to patients.
